Get started
Halozyme Therapeutics, Inc.Halozyme Therapeutics, Inc.Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

HALO chart


Full chart

HALO upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪6.00 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
15.61
Basic EPS (TTM)
3.08 USD
Net income (FY)
‪281.59 M‬ USD
Revenue (FY)
‪829.25 M‬ USD
Shares float
‪125.88 M‬
Beta (1Y)
1.42

Employees


Employees (FY)
373
Change (1Y)
−20 −5.09%
Revenue / Employee (1Y)
‪2.22 M‬ USD
Net income / Employee (1Y)
‪754.94 K‬ USD

About Halozyme Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Helen I. Torley
Website
halozyme.com
Headquarters
San Diego
Founded
1998
FIGI
BBG000CZ8W54
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

HALO news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

HALO highest yielding bonds


HALO5387960
Halozyme Therapeutics, Inc. 0.25% 01-MAR-2027
Yield to maturity
2.91%
Maturity date
Mar 1, 2027
HALO5638653
Halozyme Therapeutics, Inc. 1.0% 15-AUG-2028
Yield to maturity
−1.10%
Maturity date
Aug 15, 2028

Explore more bonds 

Sparks


Curated watchlists where HALO is featured.

See all sparks 

Frequently Asked Questions


The current price of HALO is 47.54 USD — it has increased by 0.81% in the past 24 hours. Watch Halozyme Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Halozyme Therapeutics, Inc. stocks are traded under the ticker HALO.
HALO stock has fallen by −0.08% compared to the previous week, the month change is a −2.84% fall, over the last year Halozyme Therapeutics, Inc. has showed a 28.35% increase.
We've gathered analysts' opinions on Halozyme Therapeutics, Inc. future price: according to them, HALO price has a max estimate of 75.00 USD and a min estimate of 52.00 USD. Watch HALO chart and read a more detailed Halozyme Therapeutics, Inc. stock forecast: see what analysts think of Halozyme Therapeutics, Inc. and suggest that you do with its stocks.
HALO reached its all-time high on Aug 29, 2024 with the price of 65.53 USD, and its all-time low was 1.41 USD and was reached on Aug 17, 2004. View more price dynamics on HALO chart.
See other stocks reaching their highest and lowest prices.
HALO stock is 1.87% volatile and has beta coefficient of 1.42. Track Halozyme Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Halozyme Therapeutics, Inc. there?
Today Halozyme Therapeutics, Inc. has the market capitalization of ‪6.05 B‬, it has decreased by −2.96% over the last week.
Yes, you can track Halozyme Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Halozyme Therapeutics, Inc. is going to release the next earnings report on Feb 25, 2025. Keep track of upcoming events with our Earnings Calendar.
HALO earnings for the last quarter are 1.27 USD per share, whereas the estimation was 0.99 USD resulting in a 28.12% surprise. The estimated earnings for the next quarter are 1.15 USD per share. See more details about Halozyme Therapeutics, Inc. earnings.
Halozyme Therapeutics, Inc. revenue for the last quarter amounts to ‪290.08 M‬ USD, despite the estimated figure of ‪252.17 M‬ USD. In the next quarter, revenue is expected to reach ‪288.52 M‬ USD.
HALO net income for the last quarter is ‪137.01 M‬ USD, while the quarter before that showed ‪93.25 M‬ USD of net income which accounts for 46.94% change. Track more Halozyme Therapeutics, Inc. financial stats to get the full picture.
No, HALO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 373.00 employees. See our rating of the largest employees — is Halozyme Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Halozyme Therapeutics, Inc. EBITDA is ‪558.63 M‬ USD, and current EBITDA margin is 50.94%. See more stats in Halozyme Therapeutics, Inc. financial statements.
Like other stocks, HALO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Halozyme Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Halozyme Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Halozyme Therapeutics, Inc. stock shows the buy signal. See more of Halozyme Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.